Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for allegedly misleading investors about the company's business prospects during the period from February 16, 2023, to February 12, 2025 [1][2]. Allegations - The lawsuit claims that West Pharmaceutical failed to disclose significant ongoing destocking in its high-margin HVP portfolio, contrary to its assertions of strong customer demand [2]. - It is alleged that the SmartDose device, marketed as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [2]. - The margin pressures faced by the company raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-standing customers [2]. - Positive statements made by the company regarding its business and prospects were claimed to be materially false or misleading [2]. Disclosure of Truth - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to the loss of two major CGM customers transitioning to in-house manufacturing [3]. - West also indicated that its SmartDose devices would be margin dilutive in 2025 and mentioned that steps would be taken to improve the economics of the SmartDose [3]. - Following this announcement, West's stock price fell by $123.17 per share, a decline of approximately 38%, closing at $199.11 on February 13, 2025 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 7, 2025 [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. About Robbins LLP - Robbins LLP is recognized for its work in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit due to alleged misleading statements and operational inefficiencies that impacted the company's financial performance during the specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from February 16, 2023, to February 12, 2025 [3]. - Allegations include: - The company claimed strong visibility into customer demand while actually facing significant destocking in its high-margin HVP portfolio [3]. - The SmartDose device, marketed as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [3]. - Margin pressures raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-term customers [3]. - Positive statements made by the defendants regarding the company's business and prospects were materially false or misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 7, 2025, to participate in potential recovery [4]. - Upon registration, shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that inflated the company's stock value [5].

NEW YORK, June 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=152569&from=4CLA ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1] Group 1: Class Action Details - Investors who bought West common stock between February 16, 2023, and February 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4] Group 2: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5] - Specific claims include that West was experiencing significant destocking in its high-margin products, contrary to its public statements, and that operational inefficiencies were negatively impacting profit margins [5] - The lawsuit asserts that these misleading statements led to investor damages when the true situation was revealed [5]

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that negatively impacted investors between February 16, 2023, and February 12, 2025 [1][2]. Summary by Sections Class Definition - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud during the specified period [2]. Case Details - The complaint alleges that West Pharmaceutical Services made false statements and concealed significant issues, including: - The company was experiencing ongoing destocking in its high-margin HVP portfolio, contrary to claims of strong visibility into customer demand [3]. - The SmartDose device, marketed as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [3]. - Margin pressures raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-term customers [3]. - Positive statements made by the defendants regarding the company's business and prospects were materially false or misleading [3]. Next Steps - Investors who suffered losses during the relevant timeframe have until July 7, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders and consistently ranking among the top securities litigation firms in the U.S. [5].

West Pharmaceutical Services (WST) closed the last trading session at $223.77, gaining 2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $284 indicates a 26.9% upside potential.The average comprises 10 short-term price targets ranging from a low of $245 to a high of $355, with a standard deviation of $34.94. While the lowest estimate indicates an increase of 9.5% from the current ...

NEW YORK, June 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a mem ...

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=151935&fr ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements during the class period from February 16, 2023, to February 12, 2025 [1]. Group 1: Allegations - The complaint alleges that West Pharmaceutical Services claimed strong visibility into customer demand while actually experiencing significant destocking in its high-margin HVP portfolio [1]. - The SmartDose device, positioned as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [1]. - Margin pressures from these issues raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with longstanding customers [1]. - Positive statements made by the defendants regarding the company's business and prospects were deemed materially false or misleading [1]. Group 2: Class Action Details - Shareholders who purchased shares of WST during the specified class period are encouraged to register for the class action, with a deadline of July 7, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased West common stock between February 16, 2023, and February 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lead plaintiff must file a motion with the Court by July 7, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5]. - It is claimed that West was experiencing significant destocking in its high-margin products, contrary to its public statements attributing issues to temporary COVID-related factors [5]. - The operational inefficiencies of the SmartDose device were said to be dilutive to profit margins, leading to potential restructuring activities and exit from key contracts [5].